All
The Value of Testicular Self-Exams and Early Detection from the Survivorship Perspective
July 21st 2016There’s been some debate in recent years about the true value and effectiveness of certain types of cancer screenings. This is, of course, a perfectly reasonable thing to be doing both in the name of advancing medical science, and especially in an environment where there's so much downward pressure on the costs of healthcare.
Early Immunotherapy Data: 8 Questions With a Bladder Cancer Expert
July 19th 2016The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.